Estuardo Aguilar-Cordova compensation by year
Candel Therapeutics Summary Compensation Table · all 2 fiscal years held| Component | FY2020 | FY2021 |
|---|---|---|
| Salary | $444,903 | $520,192 |
| Bonus | $104,000 | $0 |
| Stock awards | $0 | $0 |
| Option awards | $0 | $0 |
| Non-equity incentive | $191,250 | $0 |
| Pension and deferred compensation | $0 | $0 |
| All other | $0 | $6,194 |
| Total | $740,153 | $526,386 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Candel Therapeutics, Inc. DEF 14A filed September 2, 2022, accession 0001193125-22-237187, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Candel Therapeutics, Inc. filed document, accession 0001193125-22-237187. Every figure is read from that document and cited to the page and table it appears in. Filed September 2, 2022.
Insider transactions since the last proxy
44 Form 4 lines since the FY2021 proxy (filed September 2, 2022)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-02-21 | Disposition to the issuer | — | 10,583 | $12.02 | 162,929 |
| 2025-02-21 | Disposition to the issuer | — | 10,582 | $12.02 | 120,861 |
| 2025-02-10 | Disposition to the issuer | — | 31,335 | $8.61 | 60,000 |
| 2024-12-27 | Disposition to the issuer | — | 50,000 | $8.85 | 173,512 |
| 2024-12-27 | Disposition to the issuer | — | 50,000 | $8.85 | 131,443 |
| 2024-12-26 | Disposition to the issuer | — | 50,000 | $9.01 | 223,512 |
| 2024-12-26 | Disposition to the issuer | — | 50,000 | $9.01 | 181,443 |
| 2024-12-24 | Disposition to the issuer | — | 50,000 | $8.82 | 273,512 |
The 8 most recent of 44 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Candel Therapeutics’s named executive officers, FY2021
as the company reported each| Named executive officer | Role | FY2021 total |
|---|---|---|
| Paul Tak | President and Chief Executive Officer | $956,800 |
| Estuardo Aguilar-Cordova · this page | Founder and Former Chief Executive Officer and Chief Scientific Officer (5) | $526,386 |
| John Canepa | Chief Financial Officer | $449,123 |
Board service
Candel Therapeutics board · FY2023| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2023 | $35,000 | $0 | $13,186 | — | $48,186 |
Each year as the company reported it in Candel Therapeutics's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: Candel Therapeutics pays directors a $35,000 cash retainer. As stated in Candel Therapeutics's FY2023 proxy.
The full Candel Therapeutics compensation record
free company briefThis page is one person within Candel Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Candel Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.